TY - JOUR
T1 - Dual therapeutic effects of c-10068, a dextromethorphan derivative, against post-traumatic nonconvulsive seizures and neuroinflammation in a rat model of penetrating ballistic-like brain injury
AU - Lu, Xi Chun May
AU - Shear, Deborah A.
AU - Graham, Philip B.
AU - Bridson, Gary W.
AU - Uttamsingh, Vinita
AU - Chen, Zhiyong
AU - Leung, Lai Yee
AU - Tortella, Frank C.
N1 - Publisher Copyright:
© Mary Ann Liebert, Inc. 2015.
PY - 2015/10/15
Y1 - 2015/10/15
N2 - Post-traumatic seizures can exacerbate injurious outcomes of severe brain trauma, yet effective treatments are limited owing to the complexity of the pathology underlying the concomitant occurrence of both events. In this study, we tested C10068, a novel deuterium-containing analog of (+)-N-methyl-3-ethoxymorphinan, in a rat model of penetrating ballistic-like brain injury (PBBI) and evaluated the effects of C-10068 on PBBI-induced nonconvulsive seizures (NCS), acute neuroinflammation, and neurofunctional outcomes. NCS were detected by electroencephalographic monitoring. Neuroinflammation was evaluated by immunohistochemical markers, for example, glial fibrillary acidic protein and major histocompatibility complex class I, for activation of astrocytes and microglia, respectively. Neurofunction was tested using rotarod and Morris water maze tasks. Three infusion doses of C-10068 (1.0, 2.5, and 5.0mg/kg/h×72h) were tested in the antiseizure study. Neuroinflammation and neurofunction were evaluated in animals treated with 5.0mg/kg/h×72h C-10068. Compared to vehicle treatment, C-10068 dose dependently reduced PBBI-induced NCS incidence (40-50%), frequency (20-70%), and duration (30-82%). The most effective antiseizure dose of C-10068 (5.0mg/kg/h×72h) also significantly attenuated hippocampal astrocyte activation and perilesional microglial reactivity post-PBBI. Within C-10068-treated animals, a positive correlation was observed in reduction in NCS frequency and reduction in hippocampal astrocyte activation. Further, C-10068 treatment significantly attenuated astrocyte activation in seizure-free animals. However, C-10068 failed to improve PBBI-induced motor and cognitive functions with the dosing regimen used in this study. Overall, the results indicating that C-10068 exerts both potent antiseizure and antiinflammatory effects are promising and warrant further investigation.
AB - Post-traumatic seizures can exacerbate injurious outcomes of severe brain trauma, yet effective treatments are limited owing to the complexity of the pathology underlying the concomitant occurrence of both events. In this study, we tested C10068, a novel deuterium-containing analog of (+)-N-methyl-3-ethoxymorphinan, in a rat model of penetrating ballistic-like brain injury (PBBI) and evaluated the effects of C-10068 on PBBI-induced nonconvulsive seizures (NCS), acute neuroinflammation, and neurofunctional outcomes. NCS were detected by electroencephalographic monitoring. Neuroinflammation was evaluated by immunohistochemical markers, for example, glial fibrillary acidic protein and major histocompatibility complex class I, for activation of astrocytes and microglia, respectively. Neurofunction was tested using rotarod and Morris water maze tasks. Three infusion doses of C-10068 (1.0, 2.5, and 5.0mg/kg/h×72h) were tested in the antiseizure study. Neuroinflammation and neurofunction were evaluated in animals treated with 5.0mg/kg/h×72h C-10068. Compared to vehicle treatment, C-10068 dose dependently reduced PBBI-induced NCS incidence (40-50%), frequency (20-70%), and duration (30-82%). The most effective antiseizure dose of C-10068 (5.0mg/kg/h×72h) also significantly attenuated hippocampal astrocyte activation and perilesional microglial reactivity post-PBBI. Within C-10068-treated animals, a positive correlation was observed in reduction in NCS frequency and reduction in hippocampal astrocyte activation. Further, C-10068 treatment significantly attenuated astrocyte activation in seizure-free animals. However, C-10068 failed to improve PBBI-induced motor and cognitive functions with the dosing regimen used in this study. Overall, the results indicating that C-10068 exerts both potent antiseizure and antiinflammatory effects are promising and warrant further investigation.
KW - C-10068
KW - EEG
KW - dextromethorphan
KW - neuroinflammation
KW - nonconvulsive seizures
KW - penetrating brain injury
UR - http://www.scopus.com/inward/record.url?scp=84941593526&partnerID=8YFLogxK
U2 - 10.1089/neu.2014.3766
DO - 10.1089/neu.2014.3766
M3 - Article
C2 - 25794265
AN - SCOPUS:84941593526
SN - 0897-7151
VL - 32
SP - 1621
EP - 1632
JO - Journal of Neurotrauma
JF - Journal of Neurotrauma
IS - 20
ER -